AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data
MELODY Data Music To Companies’ Ears
Executive Summary
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
You may also be interested in...
Five (Non-COVID) Clinical Trial Hits Of 2021
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
Five (Non-COVID) Clinical Trial Hits Of 2021
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, Scrip takes a look at five of the more notable clinical trial hits of the year that got readers clicking.
Sobi Loses Private Equity Buyout
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.